Alcoholic Liver Diseases Clinical Trial
Official title:
Randomised Controlled Trial Assessing the Effect of S-adenosylmethionine Plus Choline in Treatment of Patients With Alcoholic Liver Disease
The study will assess the effect of treatment with formulation containing S-Adenosyl
methionine and choline, on patients with alcoholic liver disease.
Half of the patients included will receive named formulation once daily for 24 weeks while
other half will receive placebo.
Choline and S-Adenosyl methionine are nutrients both showing hepatoprotective effects.
Choline helps liver metabolise glucose and lipids and repair cell membrane. S-Adenosyl
methionine is essential for the synthesis of glutathione, a main cellular antioxidant showing
its protective effect against free radicals, among others in liver tissue. Furthermore
S-Adenosyl methionine is involved in regulation of hepatocyte growth, differentiation, and
death. It also enables endogenous production of small amount of choline. Although human
organism has capacity for production of small amount of S-Adenosyl methionine, damaged liver
can not produce it or produce it insufficient amounts.
Having this in mind it can be hypothesised that administration of choline and S-Adenosyl
methionine can be beneficial in patients with alcoholic liver disease.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01701687 -
Biomarkers for the Prognosis of Decompensated Alcoholic Liver Disease
|
N/A |